How do I buy Inovio Pharma (INO) stock?

Buying Inovio Pharma (INO) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "INO", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy INO by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if INO is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Inovio Pharma (INO) Stock

Q: What is the minimum investment for INO on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Inovio Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NSQ · INO

Trade INO

Key stats

Market cap: $149.93M
Price / Earnings ratio: -2.5x
EPS (TTM): -$0.91
Volume: Loading
52-week high: $2.72
52-week low: $0.56
EPS vs analyst estimate: +10.2%Q3 FY25 · -$0.44 vs -$0.49

Source: third-party data provider, as of November 7, 2026

EPS estimate: analyst consensus

Compare with INO

Technical indicators

RSI 14: 57.69
MACD 12/26/9: 0.09
EMA 9 of MACD: 0.00
MACD histogram: 0.09
SMA 50: $1.17; Price above SMA 50
EMA 50: $1.14; Price above EMA 50
SMA 200: $1.27; Price above SMA 200
EMA 200: $1.34; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 2 analyst ratings

Strong Sell0

Sell0

Hold0

Buy2

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

12M8M4M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

595M393M196M0

Revenue to Profit

2025

$65343.0

Revenue

$0.0

Cost of revenue

$65343.0

Gross profit

$0.0

Operating expenses

$-84.9M

Net income

Earnings

EPS forecast

Actual EPS

$-0.51

$-0.74

Q1FY25

$-0.61

$-0.62

Q2FY25

$-0.44

$-0.49

Q3FY25

$-0.36

Q4FY25

$-0.34

Q1FY26

The market is expecting earnings per share of -$0.34 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Inovio Pharma

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100 met primary and secondary endpoints for all evaluable subjects in REVEAL 1, the first of two, Phase 3 trials for precancerous cervical dysplasia, demonstrating ability to destroy and clear both high-grade cervical lesions and the underlying high-risk HPV-16/18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea.

SectorHealthcare

IndustryBiotechnology

Employees112

CEODr. Jacqueline E. Shea Ph.D.

IPO DateFeb 12, 1998

HeadquartersPlymouth Meeting, PA

Key Executives

Name	Title	Year Born
Dr. Jacqueline E. Shea Ph.D.	CEO, President & Director	1966
Dr. Laurent M. Humeau Ph.D.	Chief Scientific Officer & Chairman of the Scientific Advisory Board	1967
Mr. Peter D. Kies	Chief Financial Officer	1963
Dr. Michael Sumner B.S., M.B.A., M.D.	Chief Medical Officer & Head of Development	1965
Mr. Robert L. Crotty J.D.	General Counsel, Corporate Secretary & Chief Compliance Officer	1974
Ms. Jennie Willson	Director of Communications	—
Mr. E. J. Brandreth MBA	Senior Vice President of Quality Assurance	—
Dr. Jeffrey Skolnik M.D.	Senior Vice President of Clinical Development	—
Mr. Robert J. Juba Jr.	Senior Vice President of Biological Manufacturing & Clinical Supply Management	—
Mr. Shawn D. Bridy M.A., M.B.A.	Senior Vice President of Business Development	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											+7.4	-24.4
2022	-20.4	-21.5	+10.8	-28.2	-37.2	-1.7	+4.8	+19.9	-26.0	+25.6	-3.8	-18.8
2023	+9.2	-24.6	-33.9	-1.6	-21.4	-21.9	+21.8	-9.5	-13.8	-6.4	+5.3	+28.0
2024	-20.4	+66.9	+45.3	-12.7	-12.6	-20.5	+23.8	-27.9	-10.1	-6.0	-20.7	-57.9
2025	+14.8	-0.5	-11.4	+29.3	+5.8	-2.9	-30.4	+65.7	-8.9	-0.8	-17.6	-9.4
2026	-3.6	+6.5	+0.0	-35.6	+19.1	-14.1	-42.9	+81.4	-8.3	-50.4	-23.3

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Inovio Pharma (INO) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "INO", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy INO by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Inovio Pharma from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Inovio Pharma (INO) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track INO's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Inovio Pharma (INO) Stock

Key stats

Compare with INO

Recent news

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings

Bet on 4 Top-Ranked Stocks With Rising P/E

Bet on 4 Top-Ranked Stocks With Rising P/E

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Bet on 5 Top-Ranked Stocks With Rising P/E

Bet on 5 Top-Ranked Stocks With Rising P/E

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Bet on 5 Top-Ranked Stocks With Rising P/E

Bet on 5 Top-Ranked Stocks With Rising P/E

About Inovio Pharma

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade